Literature DB >> 16170521

[Does acetylsalicylic acid have a negative influence on photodynamic therapy?].

U Löw1, J K Kohlhof, K W Ruprecht.   

Abstract

BACKGROUND: Non-thermal photodynamic therapy (PDT) is presently being used for the treatment of certain forms of age-related macular degeneration (AMD). This therapy results in selective occlusion of newly growing vessels. Due to this effectiveness of PDT the question came up whether inhibitors of platelet aggregation have an influence on PDT. PATIENTS AND METHODS: Our retrospective study included 60 patients with mainly classic subfoveal choroidal neovascularizations (CNV) due to AMD. All patients were treated by PDT. Thirty patients took acetylsalicylic acid (aspirin) because of their general disease before and during treatment. In the control group none of the patients took acetylsalicylic acid.
RESULTS: Best corrected visual acuity and measured dimension of the choroidal neovascularization showed before beginning PDT no statistically significant difference (visual acuity p=0.676; dimension of CNV p=0.678). Also no significant difference existed between visual acuity (p=0.412; p=0.226; p=0.969) and CNV (p=0.871; p=0.245; p=0.323) at the follow-up examination.
CONCLUSION: Our study has shown that acetylsalicylic acid does not have any effect on PDT treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16170521     DOI: 10.1007/s00347-005-1256-9

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  15 in total

1.  Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Macular Photocoagulation Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1991-09

Review 2.  [Photodynamic therapy. Minimally invasive treatment of choroidal neovascularization].

Authors:  U Schmidt-Erfurth
Journal:  Ophthalmologe       Date:  1998-10       Impact factor: 1.059

3.  Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial.

Authors: 
Journal:  Lancet       Date:  2000-04-15       Impact factor: 79.321

Review 4.  Antiplatelet therapy.

Authors:  A I Schafer
Journal:  Am J Med       Date:  1996-08       Impact factor: 4.965

5.  Modes of action of aspirin-like drugs: salicylates inhibit erk activation and integrin-dependent neutrophil adhesion.

Authors:  M H Pillinger; C Capodici; P Rosenthal; N Kheterpal; S Hanft; M R Philips; G Weissmann
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

6.  Cholesterol metabolism in cancer cells in monolayer culture. III. Low-density lipoprotein metabolism.

Authors:  D Gal; P C MacDonald; J C Porter; E R Simpson
Journal:  Int J Cancer       Date:  1981-09-15       Impact factor: 7.396

7.  Clinicopathological findings of choroidal neovascularisation following verteporfin photodynamic therapy.

Authors:  F Gelisken; B A Lafaut; W Inhoffen; M Voelker; S Grisanti; K U Bartz-Schmidt
Journal:  Br J Ophthalmol       Date:  2004-02       Impact factor: 4.638

8.  Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumor.

Authors:  K R Weishaupt; C J Gomer; T J Dougherty
Journal:  Cancer Res       Date:  1976-07       Impact factor: 12.701

9.  Immunohistopathologic evaluation of choroidal neovascular membranes following verteporfin-photodynamic therapy.

Authors:  Salvatore Grisanti; Olcay Tatar; Serap Canbek; Bart A Lafaut; Faik Gelisken; Werner Inhoffen; Peter Szurman; Sabin Aisenbrey; Jolanta Oficjalska-Mlynczak; Karl Ulrich Bartz-Schmidt
Journal:  Am J Ophthalmol       Date:  2004-05       Impact factor: 5.258

10.  Evidence for a major role of plasma lipoproteins as hematoporphyrin carriers in vivo.

Authors:  G Jori; M Beltramini; E Reddi; B Salvato; A Pagnan; L Ziron; L Tomio; T Tsanov
Journal:  Cancer Lett       Date:  1984-10       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.